Glaukos Corp stock (US3773221029): Insider files Form 144 for 5,000-share sale

Glaukos Corp (NYSE: GKOS) insider filed a Form 144 notice on May 11, 2026, to sell 5,000 common shares valued at $675,000, amid upcoming investor conference participation.

Glaukos Corp, an ophthalmic medical technology firm, saw an insider file a Form 144 notice with the SEC on May 11, 2026, proposing the sale of 5,000 common shares at an aggregate market value of $675,000. The filing, submitted via Fidelity Brokerage Services LLC, indicates an approximate sale date of May 11, 2026, on the NYSE, with shares acquired that day through options granted on June 2, 2016. This routine disclosure reflects standard insider transaction reporting under Rule 144, according to Stock Titan as of 05/11/2026.

Separately, Glaukos announced its participation in upcoming investor conferences, highlighting ongoing engagement with the investment community, as detailed in a Business Wire release dated May 12, 2026. The company, listed on NYSE under ticker GKOS, focuses on therapies for glaucoma and retinal diseases, maintaining visibility for US investors through such events, according to Business Wire as of 05/12/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Glaukos Corporation
• Sector/industry: Ophthalmic medical technology
• Headquarters/country: United States
• Core markets: Glaucoma, corneal, retinal treatments
• Home exchange/listing venue: NYSE (GKOS)
• Trading currency: USD

Glaukos Corp: core business model

Glaukos Corp develops and commercializes novel therapies for glaucoma, corneal disorders, and retinal diseases. The company's platform includes microinvasive glaucoma surgery (MIGS) devices and pharmaceutical implants, targeting the large US ophthalmology market where glaucoma affects over 3 million patients. Its business model emphasizes innovation in sustained-release drug delivery and minimally invasive procedures, with products like iStent gaining adoption among US eye care professionals.

Headquartered in the US, Glaukos generates revenue primarily from device sales and implants used in outpatient settings, benefiting from strong reimbursement dynamics in the Medicare-heavy glaucoma segment. The firm's focus on proprietary technologies positions it as a key player for US investors interested in medtech growth areas.

Main revenue and product drivers for Glaukos Corp

Key products include the iStent inject system, approved for cataract surgery patients with mild to moderate glaucoma, driving the majority of US revenue. Additional drivers encompass retinal implants and corneal therapies in development, with clinical data supporting expanded indications. Glaukos reported growth in procedure volumes tied to these products in prior periods, underscoring demand in the aging US population.

Revenue is bolstered by partnerships with US surgical centers and a direct sales force targeting high-volume ophthalmologists. The company's pipeline advancements, including next-gen MIGS devices, represent potential catalysts for future topline expansion relevant to NYSE-listed medtech exposure.

Industry trends and competitive position

The ophthalmic medtech sector sees rising demand for less invasive glaucoma treatments amid US surgeon preferences shifting from traditional trabeculectomy. Glaukos competes with firms like Alcon and Bausch + Lomb, differentiating through its micro-scale implants that enable same-day procedures. Market data indicates MIGS procedures growing at double-digit rates in the US, per sector reports.

Why Glaukos Corp matters for US investors

As a NYSE-listed pure-play in glaucoma innovation, Glaukos offers US investors targeted exposure to a $10B+ addressable market driven by demographic aging and procedure shifts. Its US-centric revenue, over 90% domestic, aligns with Medicare reimbursement tailwinds and elective surgery recovery post-pandemic.

Conclusion

The recent Form 144 filing signals a standard insider transaction at Glaukos Corp, coinciding with proactive investor outreach via conferences. These developments maintain market visibility for the ophthalmic innovator amid a competitive US medtech landscape. Investors track such disclosures and events as part of routine monitoring for NYSE: GKOS.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.